# Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease

> **NCT01421719** · PHASE4 · COMPLETED · sponsor: **Stanford University** · enrollment: 20 (actual)

## Conditions studied

- Parkinson's Disease
- Neurogenic Bladder
- Urinary Incontinence
- Clostridium Botulinum Toxin Adverse Reaction

## Interventions

- **DRUG:** Cystoscopic injection of Botox into the urinary bladder

## Key facts

- **NCT ID:** NCT01421719
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2011-05
- **Final completion:** 2011-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01421719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01421719, "Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01421719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*